Analysis of the molecular mechanism of Pudilan (PDL) treatment for COVID-19 by network pharmacology tools - 18/06/20
, Yue Wu a, Yu Gu a, Qi Lv a, Feifei Qi a, Shuran Gong a, Xiuping Chen b, ⁎
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.
Conéctese para beneficiarse!
Graphical abstract |
Highlights |
• | Pudilan (PDL) was proven to be useful in the treatment of 2019 novel coronavirus disease (COVID-19). |
• | Pudilan (PDL) might inhibit the cytokine storm in 2019 novel coronavirus disease (COVID-19) by affecting Interleukin-1β (IL-1β) and related proteins. |
• | Pudilan (PDL) might prevent the entry of SARS-CoV-2 into cells by affecting angiotensin I converting enzyme 2 (ACE2). |
• | Pudilan (PDL) might also moderate human immune system with traditional Chinese medicine theory. |
Abstract |
Background |
Pudilan (PDL), a four-herb prescription with the traditional function of heat-clearing and detoxifying, has been clinically used as an anti-SARS-CoV-2 infectory agent in China. PDL might also have therapeutic potentials for COVID-19 while the underlying mechanisms remain to be clarified.
Methods |
We used network pharmacology analysis and selected 68 co-targeted genes/proteins as targets of both PDL and COVID-19. These co-targeted genes/proteins were predicted by SwissDock Server for their high-precision docking simulation, and analyzed by STRING for proteins to protein interaction (PPI), pathway and GO (gene ontology) enrichment. The therapeutic effect for PDL treatment on COVID-19 was validated by the TCMATCOV (TCM Anti COVID-19) platform.
Results |
PDL might prevent the entrance of SARS-CoV-2 entry into cells by blocking the angiotensin-converting enzyme 2 (ACE2). It might inhibit the cytokine storm by affecting C-reactive protein (CRP), interferon-γ (IFN-γ), interleukin- 6 (IL-6), interleukin- 10 (IL-10), tumor necrosis factor (TNF), epidermal growth factor receptor (EGFR), C-C motif chemokine ligand 5 (CCL5), transforming growth factor-β1 (TGFβ1), and other proteins. PDL might moderate the immune system to shorten the course of the disease, delay disease progression, and reduce the mortality rate.
Conclusion |
PDL might have a therapeutic effect on COVID-19 through three aspects, including the moderate immune system, anti-inflammation, and anti-virus entry into cells.
El texto completo de este artículo está disponible en PDF.Abbreviations : ACE2, ARDS, BXTM, COVID-19, LHQW, HSZF, PDL, SARS-CoV-2, SFJD, TCM
Keywords : SARS-CoV-2 infection, COVID-19, Traditional Chinese herbs, Targeted therapy, Network pharmacology
Esquema
Vol 128
Artículo 110316- août 2020 Regresar al número
Artículo precedente
- Docosahexaenoic acid protects against palmitate-induced mitochondrial dysfunction in diabetic cardiomyopathy
- Ting Gui, Yunlun Li, Shijun Zhang, Nan Zhang, Ying Sun, Fengzhen Liu, Qingfa Chen, Zhibo Gai
- Staurosporine and venetoclax induce the caspase-dependent proteolysis of MEF2D-fusion proteins and apoptosis in MEF2D-fusion (+) ALL cells
- Naoyuki Tange, Fumihiko Hayakawa, Takahiko Yasuda, Koya Odaira, Hideyuki Yamamoto, Daiki Hirano, Toshiyasu Sakai, Seitaro Terakura, Shinobu Tsuzuki, Hitoshi Kiyoi
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.